Trastuzumab emtansine: indication of major added benefit in 1 subpopulation

Added benefit not proven in 3 further subpopulations because appropriate comparator therapies were not implemented

2014-04-07

(Press-News.org) The antibody-drug conjugate trastuzumab emtansine (trade name: Kadcyla) has been approved since November 2013 for the treatment of patients with unresectable, locally advanced or metastatic breast cancer that is HER2-positive, i.e. that overexpresses the human epidermal growth factor receptor 2. Patients must have already received trastuzumab or a taxane – alone or in combination. They should also have already received treatment for the locally advanced or metastatic disease or have developed disease recurrence during or within six months of completing adjuvant therapy.

The Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the added benefit of the conjugate in these patients. It distinguished between four subpopulations and appropriate comparator therapies. IQWiG found an indication of a major added benefit for patients who have received previous treatment with trastuzumab and taxanes and with anthracyclines. For the remaining three subpopulations, an added benefit is not proven.

Antibody combined with mitotic inhibitor

If the cancer cells in locally advanced breast cancer or breast cancer that has already formed metastases produce excessive quantities of the growth factor receptor HER2, the disease progresses particularly aggressively because the cells multiply rapidly and hardly respond to conventional chemotherapy. In this HER2-positive breast cancer, the patient can be treated with the antibody drug trastuzumab, which blocks the receptor.

However, this is often not sufficient to stop the carcinoma from spreading. The drug manufacturer now combined trastuzumab with a strong cell division inhibitor: Whereas the antibody aims to block the receptor from outside the cell, the inhibitor is designed to destroy the tumour cells from within. IQWiG was commissioned to find out in an early benefit assessment whether, and if so, which patients benefit from this new treatment.

Different comparator therapy depending on stage and pretreatment

Depending on the stage of the breast cancer and the previous treatments received, the G-BA distinguished between four subpopulations, each with its own appropriate comparator therapy. In locally advanced, unresectable breast cancer without metastases, the new conjugate was to be compared with radiotherapy. In metastatic breast cancer that has already been treated with anthracyclines, taxanes and trastuzumab, chemotherapy with lapatinib and capecitabine was the appropriate comparator therapy.

In metastatic breast cancer that has already been treated with taxanes and trastuzumab, but not with anthracyclines, the G-BA specified an anthracycline as comparator therapy – unless this treatment was not an option for the patients. Then the conjugate was to be compared with a treatment tailored to the individual patient under consideration of the approval of the drugs used.

Added benefit could only be derived for one subpopulation

The manufacturer presented no relevant data for three of the four subpopulations: In locally advanced unresectable breast cancer, it envisaged lapatinib and capecitabine as comparator therapy instead of radiotherapy. It also considered this combination to be suitable for patients who have not yet received anthracyclines. However, this contradicts the approval of lapatinib, according to which treatment with lapatinib and capecitabine always has to be preceded by a treatment including anthracyclines. These deviations from the appropriate comparator therapies were not sufficiently justified so that an added benefit of trastuzumab emtansine in these cases is not proven.

For patients with metastatic breast cancer who have already received anthracyclines, the manufacturer cited results from the EMILIA study. Patients who have been pretreated with anthracyclines and now received either the conjugate or lapatinib and capecitabine also participated in this open-label, randomized controlled trial.

Positive effects predominate

This study showed both positive and negative effects of trastuzumab emtansine. The positive effects regarding the outcome categories "mortality", "health-related quality of life" and "serious or severe side effects" together provide an indication of a major added benefit. One out of two women who received trastuzumab emtansine was still alive after 31 months – compared with 24 months under lapatinib and capecitabine. Severe hand-foot syndrome, which can be caused by chemotherapy, was also considerably less common than in the comparator group.

This was offset by a hint of greater harm in non-serious and non-severe side effects. This harm was far from outweighing the benefit because these were mainly mild cases of nose bleed.

Overall, there was an indication of a major added benefit of trastuzumab emtansine – but only for patients with metastatic HER2-positive breast cancer who have already been treated with anthracyclines, taxanes and trastuzumab.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G BA then decides on the extent of the added benefit, thus completing the early benefit assessment.

INFORMATION: An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website » http://www.gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on trastuzumab emtansine.

The G-BA website contains both general English-language information on benefit assessment pursuant to §35a Social Code Book (SGB) V and specific German-language information on the assessment of trastuzumab emtansine. More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on http://www.informedhealthonline.org).

If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.

ELSE PRESS RELEASES FROM THIS DATE:

Longer catch-and-release time leaves largemouth bass nests more vulnerable to predators

2014-04-07

URBANA, Ill. – During spawning season, a largemouth bass male attentively guards its nest. Recent research at the University of Illinois found that catch-and-release angling could give bass predators the perfect opportunity to consume the young. In fact, the time spent away from the nest during a catch-and-release event and the subsequent exhaustion it creates for the male are critical to the survival of the embryos, particularly in lakes with high densities of brood predators. "One of the main conclusions of the study was that in a lake where there are very few brood ...

Next-generation glaucoma therapeutics hold considerable promise

2014-04-07

New Rochelle, NY, April 7, 2014—Elevated pressure in the eye is the most common risk factor for glaucoma, an optic neuropathy that can cause blindness and affects more than 67 million people worldwide. Elevated eye pressure in glaucoma develops due to abnormal functioning of the trabecular meshwork (TM) causing intraocular fluid to back up. Next-generation glaucoma drugs will target the finely tuned mechanisms of the TM that maintain normal intraocular pressure, as described in an article in Journal of Ocular Pharmacology and Therapeutics, a peer-reviewed journal from ...

Experience helps restaurant managers stick with local foods

2014-04-07

Restaurant chefs and food purchasing managers who have bought local foods in the past are more likely to continue adding them to menus and store shelves, according to a team of researchers. "Past experiences will have an impact on buying local foods," said Amit Sharma, associate professor of hospitality management, Penn State. "Restaurant managers who buy local foods currently are significantly more likely to keep purchasing locally." In a study of the cost and benefits of purchasing local foods in restaurants, managers and chefs indicated that certain actions of local ...

The social circuits that track how we like people and ideas

2014-04-07

Boston – April 7, 2014 - Whether at the office, dorm, PTA meeting, or any other social setting, we all know intuitively who the popular people are – who is most liked – even if we can't always put our finger on why. That information is often critical to professional or social success as you navigate your social networks. Yet until now, scientists have not understood how our brains recognize these popular people. In new work, researchers say that we track people's popularity largely through the brain region involved in anticipating rewards. "Being able to track other ...

Slowdown of global warming fleeting

2014-04-07

The recent slowdown in the warming rate of the Northern Hemisphere may be a result of internal variability of the Atlantic Multidecadal Oscillation -- a natural phenomenon related to sea surface temperatures, according to Penn State researchers. "Some researchers have in the past attributed a portion of Northern Hemispheric warming to a warm phase of the AMO," said Michael E. Mann, Distinguished Professor of Meteorology. "The true AMO signal, instead, appears likely to have been in a cooling phase in recent decades, offsetting some of the anthropogenic warming temporarily." ...

U Of T researchers offer hope for children with previously incurable brain cancer

2014-04-07

Researchers from the University of Toronto's Department of Laboratory Medicine and Pathobiology (LMP) have defined potential treatment targets for a previously incurable form of pediatric brain cancer called Diffuse Intrinsic Pontine Glioma (DIPG). In groundbreaking research published in Nature Genetics, Dr. Cynthia Hawkins, a professor at LMP and Neuropathologist and Scientist at The Hospital for Sick Children, along with PhD candidates Pawel Buczkowicz and Patricia Rakopoulos, identified three subgroups of DIPG, each having distinct molecular features. "In the past, ...

New research shows huge disparities between the decisions made by coroners

2014-04-07

GOVERNMENT plans to overhaul the centuries-old coroner system in England and Wales have been bolstered by the findings of a leading police officer who has become a PhD researcher at the University of Huddersfield. Detailed analysis by ex-Detective Chief Superintendent Max Mclean has shown that there are huge disparities between the decisions made by coroners in differing districts, with the troubling discovery that the deaths of women are considerably less likely to be investigated at an inquest. The result is a "postcode lottery", claims Mr Mclean, who calls for a fully-fledged ...

Disruption of VISTA plays an important role in regulating immune response

2014-04-07

Researchers at the Geisel School of Medicine at Dartmouth have found that the body's immune system response was enhanced when they disrupted VISTA, a protein that prevents the immune system from overreacting. Understanding how checkpoint regulators like VISTA function is important to cancer researchers, who hope to use the immune system to attack tumors. The study, "VISTA deficiency synergizes with a nonredundant immune checkpoint pathway and leads to enhanced immune activation," will be presented on April 7, 2014 at the American Association for Cancer Research Annual Meeting ...

Henry Ford Hospital cited: World's first surgical innovators for patient safety standards

2014-04-07

DETROIT – An innovative kidney transplant technique developed by Henry Ford Hospital is credited as the first in the world to use a new set of patient safety standards coordinated by the University of Oxford in England. The standards are being assembled and offered as a framework for developing, performing and reporting surgical innovations that, unlike new medical treatments, are not under strict regulations and control. One historic example cited by the Oxford group was the introduction of tracheostomy as a surgical method of treating an obstruction in the trachea. ...

Tissue testing during breast cancer lumpectomies

2014-04-07

ROCHESTER, Minn. — Unique laboratory testing during breast cancer lumpectomies to make sure surgeons remove all cancerous tissue spares patients the need for a repeat lumpectomy in roughly 96 percent of cases at Mayo Clinic in Rochester, a success rate much higher than the rate nationally, a Mayo study shows. During the years reviewed, 13.2 percent of breast cancer lumpectomy patients nationally had to return to the operating room within a month of their initial surgery, compared to 3.6 percent at Mayo in Rochester, which uses a technique called frozen section analysis ...